JP2020138981A5 - - Google Patents

Download PDF

Info

Publication number
JP2020138981A5
JP2020138981A5 JP2020100961A JP2020100961A JP2020138981A5 JP 2020138981 A5 JP2020138981 A5 JP 2020138981A5 JP 2020100961 A JP2020100961 A JP 2020100961A JP 2020100961 A JP2020100961 A JP 2020100961A JP 2020138981 A5 JP2020138981 A5 JP 2020138981A5
Authority
JP
Japan
Prior art keywords
preparation
preparation according
concentration
antibody
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020100961A
Other languages
English (en)
Japanese (ja)
Other versions
JP7590125B2 (ja
JP2020138981A (ja
Filing date
Publication date
Priority claimed from JP2019547137A external-priority patent/JP2020509025A/ja
Application filed filed Critical
Publication of JP2020138981A publication Critical patent/JP2020138981A/ja
Publication of JP2020138981A5 publication Critical patent/JP2020138981A5/ja
Priority to JP2023030012A priority Critical patent/JP2023060016A/ja
Application granted granted Critical
Publication of JP7590125B2 publication Critical patent/JP7590125B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020100961A 2017-03-01 2020-06-10 モノクローナル抗体製剤 Active JP7590125B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023030012A JP2023060016A (ja) 2017-03-01 2023-02-28 モノクローナル抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762465269P 2017-03-01 2017-03-01
US62/465,269 2017-03-01
JP2019547137A JP2020509025A (ja) 2017-03-01 2018-02-28 モノクローナル抗体製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019547137A Division JP2020509025A (ja) 2017-03-01 2018-02-28 モノクローナル抗体製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023030012A Division JP2023060016A (ja) 2017-03-01 2023-02-28 モノクローナル抗体製剤

Publications (3)

Publication Number Publication Date
JP2020138981A JP2020138981A (ja) 2020-09-03
JP2020138981A5 true JP2020138981A5 (enExample) 2021-02-25
JP7590125B2 JP7590125B2 (ja) 2024-11-26

Family

ID=61868490

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019547137A Pending JP2020509025A (ja) 2017-03-01 2018-02-28 モノクローナル抗体製剤
JP2020100961A Active JP7590125B2 (ja) 2017-03-01 2020-06-10 モノクローナル抗体製剤
JP2023030012A Pending JP2023060016A (ja) 2017-03-01 2023-02-28 モノクローナル抗体製剤
JP2023034558A Pending JP2023071916A (ja) 2017-03-01 2023-03-07 モノクローナル抗体製剤
JP2025014959A Pending JP2025072446A (ja) 2017-03-01 2025-01-31 モノクローナル抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019547137A Pending JP2020509025A (ja) 2017-03-01 2018-02-28 モノクローナル抗体製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023030012A Pending JP2023060016A (ja) 2017-03-01 2023-02-28 モノクローナル抗体製剤
JP2023034558A Pending JP2023071916A (ja) 2017-03-01 2023-03-07 モノクローナル抗体製剤
JP2025014959A Pending JP2025072446A (ja) 2017-03-01 2025-01-31 モノクローナル抗体製剤

Country Status (10)

Country Link
US (5) US20200283516A1 (enExample)
EP (2) EP3797792A1 (enExample)
JP (5) JP2020509025A (enExample)
KR (1) KR102589598B1 (enExample)
CN (2) CN112057419B (enExample)
AU (2) AU2018227036B2 (enExample)
BR (1) BR112019018022A2 (enExample)
CA (2) CA3054386A1 (enExample)
MX (1) MX2019010282A (enExample)
WO (1) WO2018158332A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
RU2021125449A (ru) 2014-10-01 2021-09-16 Медиммьюн Лимитед Антитела к тикагрелору и способы применения
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US10493149B2 (en) 2017-04-11 2019-12-03 Kiniksa Pharmaceuticals, Ltd. Stable anti-OSMR antibody formulation
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
CN120267816A (zh) * 2018-09-14 2025-07-08 田边三菱制药株式会社 含有人抗il-33单克隆抗体的医药用组合物
EP3852617B1 (en) * 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Use of antibody fragments for reversing ticagrelor activity
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
EP4121543A4 (en) 2020-03-17 2024-04-24 Xbrane Biopharma AB NOVEL COMBINATION OF TIS SEQUENCE AND SIGNAL PEPTIDE SEQUENCE TO EXPRESS RECOMBINANT PROTEIN
EP4126943B1 (en) 2020-03-23 2026-04-22 MedImmune Limited Methods for treating atopic dermatitis and related disorders
CA3097453A1 (en) 2020-03-23 2021-09-23 Medimmune Limited Methods for treating atopic dermatitis and related disorders
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
WO2021228760A1 (en) * 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
CN116997352A (zh) * 2021-03-24 2023-11-03 Jcr制药股份有限公司 稳定的水性药物组合物或冷冻干燥药物组合物
GB202108379D0 (en) 2021-06-11 2021-07-28 Medlmmune Ltd Methods for treating a topic dermatitis and related disorders
KR20240046243A (ko) 2021-08-16 2024-04-08 메디뮨 엘엘씨 항-il-13 항체 제제
EP4408885A1 (en) 2021-09-28 2024-08-07 MedImmune Limited Methods for treating atopic dermatitis and related disorders
CN119095584A (zh) * 2022-12-01 2024-12-06 天境生物科技(杭州)有限公司 抗gm-csf抗体的液体药物配制品及其用途
JP7548475B1 (ja) 2023-03-16 2024-09-10 小野薬品工業株式会社 抗体製剤
CN121846262A (zh) * 2026-01-05 2026-04-14 上海生物制品研究所有限责任公司 抗呼吸道合胞病毒单克隆抗体制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
WO2009026122A1 (en) * 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
RU2565809C2 (ru) * 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
SG184355A1 (en) * 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
PL2627673T3 (pl) * 2010-10-15 2018-01-31 Medimmune Ltd Terapie poprawiające funkcje płuc
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP6265970B2 (ja) 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US20170247460A1 (en) * 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Similar Documents

Publication Publication Date Title
JP6416841B2 (ja) 医薬製剤
JP7473603B2 (ja) 液体医薬組成物
US10689438B2 (en) Stable protein solution formulation containing high concentration of an anti-VEGF antibody
JP7046088B2 (ja) 抗ｒｓｖモノクローナル抗体製剤
JP2023060016A (ja) モノクローナル抗体製剤
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
JP2020518599A5 (enExample)
JP2013500947A5 (enExample)
JP2024160287A5 (enExample)
JP2019509311A5 (enExample)
JP2020532562A5 (enExample)
JP2023055977A (ja) 結晶性抗体製剤
JP2019501920A5 (enExample)
WO2019055357A1 (en) METHOD FOR THE LYOPHILIZED PHARMACEUTICAL FORMULATION OF A THERAPEUTIC PROTEIN
JP2020511443A5 (enExample)
JP2024515676A (ja) ポリペプチド製剤
TW202529766A (zh) 醫藥組合物
JP6813355B2 (ja) 新規な安定製剤
JP2021501213A5 (enExample)
JP2022519796A5 (enExample)
CN111683681A (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
JP2024538091A5 (enExample)
JP2021533149A5 (enExample)
CN116077650A (zh) 一种稳定的新冠中和抗体的药物组合物及其应用
RU2025121573A (ru) Стабильные белковые композиции антитела к pd1